Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
SGLT2 inhibitors primarily treat diabetes, with benefits also seen in heart and kidney diseases. Might they also help prevent diabetes in the first place?
As Merck & Co’s Keynote-361 study fails, attention turns to Bavencio’s Asco late-breaker and the potential of Padcev.
Roche secures a front-line liver cancer label, but rival data at Asco show that the competition isn’t resting on its laurels.